Category: All HBOC

LitAlert ~~ GeneLit.com

    • Study: Inherited gene mutations found in pancreatic cancer families in Spain
    • [No author given]
    • FORCE. XRAYS. 2020 Oct 29.

    • Under-ascertainment of breast cancer susceptibility gene carriers in a cohort of New Zealand female breast cancer patients.
    • Lattimore V, Parsons MT, Spurdle AB, Pearson J, Lehnert K, Sullivan J, Lintott C, Bawden S, Morrin H, Robinson B, Walker L.
    • Breast Cancer Res Treat. 2020 Oct 28. doi: 10.1007/s10549-020-05986-8. Epub ahead of print.

    • Breast Cancer Chemoprevention: Use and Views of Australian Women and their Clinicians.
    • Macdonald C, Saunders CM, Keogh LA, Hunter M, Mazza D, McLachlan SA, Jones SC, Nesci S, Friedlander M, Hopper JL, Emery JD, Hickey M, Milne RL, Phillips KA.
    • Cancer Prev Res (Phila). 2020 Oct 28:canprevres.0369.2020. doi: 10.1158/1940-6207.CAPR-20-0369. Epub ahead of print.

    • Specialist recommendation for chemoprevention medications in patients at familial risk of breast cancer: a cross-sectional survey in England.
    • Lee SI, Curtis H, Qureshi S, Dutton B, Qureshi N.
    • J Community Genet. 2020 Oct 28. doi: 10.1007/s12687-020-00490-4. Epub ahead of print.

    • Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study.
    • O'Shaughnessy J, Brezden-Masley C, Cazzaniga M, Dalvi T, Walker G, Bennett J, Ohsumi S.
    • Breast Cancer Res. 2020 Oct 27;22(1):114. doi: 10.1186/s13058-020-01349-9.

    • Misinterpretation of Hereditary Breast Cancer Risk and Its Association with Information Sharing Motives among Women at Low Likelihood of Carrying a BRCA1/2 Mutation.
    • Zhao J, McBride CM, Guan Y.
    • Public Health Genomics. 2020 Oct 27:1-5. doi: 10.1159/000511131. Epub ahead of print.

    • Breast Cancer Surveillance Following Ovarian Cancer in BRCA Mutation Carriers.
    • Fong A, Cass I, John C, Gillen J, Moore KM, Gangi A, Walsh C, Li AJ, Rimel BJ, Karlan BY, Amersi F.
    • Am Surg. 2020 Oct 26:3134820964208. doi: 10.1177/0003134820964208. Epub ahead of print.

    • Analysis of 11 candidate genes in 849 adult patients with suspected hereditary cancer predisposition.
    • Cavaillé M, Uhrhammer N, Privat M, Ponelle-Chachuat F, Gay-Bellile M, Lepage M, Molnar I, Viala S, Bidet Y, Bignon YJ.
    • Genes Chromosomes Cancer. 2020 Oct 25. doi: 10.1002/gcc.22911. Epub ahead of print.

    • Predictive factors for carboplatin hypersensitivity reactions in gynecologic cancers: Effect of BRCA status.
    • Rolfe M, Gegeckas C, Turner S, Orr JW Jr.
    • J Oncol Pharm Pract. 2020 Oct 25:1078155220967988. doi: 10.1177/1078155220967988. Epub ahead of print.

    • Alternative genomic diagnoses for individuals with a clinical diagnosis of Dubowitz syndrome.
    • Dyment DA, O'Donnell-Luria A, Agrawal PB, Coban Akdemir Z, Aleck KA, Antaki D, Al Sharhan H, Au PB, Aydin H, Beggs AH, Bilguvar K, Boerwinkle E, Brand H, Brownstein CA, Buyske S, Chodirker B, Choi J, Chudley AE, Clericuzio CL, Cox GF, Curry C, de Boer E, de Vries BBA, Dunn K, Dutmer CM, England EM, Fahrner JA, Geckinli BB, Genetti CA, Gezdirici A, Gibson WT, Gleeson JG, Greenberg CR, Hall A, Hamosh A, Hartley T, Jhangiani SN, Karaca E, Kernohan K, Lauzon JL, Lewis MES, Lowry RB, López-Giráldez F, Matise TC, McEvoy-Venneri J, McInnes B, Mhanni A, Garcia Minaur S, Moilanen J, Nguyen A, Nowaczyk MJM, Posey JE, Õunap K, Pehlivan D, Pajusalu S, Penney LS, Poterba T, Prontera P, Doriqui MJR, Sawyer SL, Sobreira N, Stanley V, Torun D, Wargowski D, Witmer PD, Wong I, Xing J, Zaki MS, Zhang Y; Care4Rare Consortium; Centers for Mendelian Genomics, Boycott KM, Bamshad MJ, Nickerson DA, Blue EE, Innes AM.
    • Am J Med Genet A. 2020 Oct 24. doi: 10.1002/ajmg.a.61926. Epub ahead of print.

    • BARD1 and Breast Cancer: The Possibility of Creating Screening Tests and New Preventive and Therapeutic Pathways for Predisposed Women.
    • Sniadecki M, Brzezinski M, Darecka K, Klasa-Mazurkiewicz D, Poniewierza P, Krzeszowiec M, Kmiec N, Wydra D.
    • Genes (Basel). 2020 Oct 24;11(11):E1251. doi: 10.3390/genes11111251.

    • Impact of Personalized Genetic Breast Cancer Risk Estimation With Polygenic Risk Scores on Preventive Endocrine Therapy Intention and Uptake.
    • Kim JO, Schaid DJ, Vachon CM, Cooke A, Couch FJ, Kim CA, Sinnwell JP, Hasadsri L, Stan DL, Goldenberg BA, Neal L, Grenier D, Degnim AC, Thicke LA, Pruthi S.
    • Cancer Prev Res (Phila). 2020 Oct 23:canprevres.0154.2020. doi: 10.1158/1940-6207.CAPR-20-0154. Epub ahead of print.

    • An in-depth exploration of the post-test informational needs of BRCA1 and BRCA2 pathogenic variant carriers in Asia.
    • Yuen J, Fung SM, Sia CL, Venkatramani M, Shaw T, Courtney E, Li ST, Chiang J, Tan VK, Tan BK, Ngeow J.
    • Hered Cancer Clin Pract. 2020 Oct 23;18:22. doi: 10.1186/s13053-020-00154-x.

    • ICON 9-an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy.
    • Elyashiv O, Ledermann J, Parmar G, Farrelly L, Counsell N, Feeney A, El-Khouly F, Macdonald I, Neto A, Arthur-Darkwa E, Burnett E, Jayson GC, Mileshkin L, Gourley C, Nicum S.
    • Int J Gynecol Cancer. 2020 Oct 23:ijgc-2020-002073. doi: 10.1136/ijgc-2020-002073. Epub ahead of print.

    • Inflammatory indexes as predictive factors for platinum sensitivity and as prognostic factors in recurrent epithelial ovarian cancer patients: a MITO24 retrospective study.
    • Farolfi A, Scarpi E, Greco F, Bergamini A, Longo L, Pignata S, Casanova C, Cormio G, Bologna A, Orditura M, Zavallone L, Attademo L, Gallà V, Franzese E, Pigozzi E, Loizzi V, Giorda G, Giardina D, Cioffi R, De Giorgi U.
    • Sci Rep. 2020 Oct 23;10(1):18190. doi: 10.1038/s41598-020-75316-x.

    • Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study).
    • Fasching PA, Link T, Hauke J, Seither F, Jackisch C, Klare P, Schmatloch S, Hanusch C, Huober J, Stefek A, Seiler S, Schmitt WD, Uleer C, Doering G, Rhiem K, Schneeweiss A, Engels K, Denkert C, Schmutzler RK, Hahnen E, Untch M, Burchardi N, Blohmer JU, Loibl S; GBG and AGO-B.
    • Ann Oncol. 2020 Oct 21:S0923-7534(20)42963-1. doi: 10.1016/j.annonc.2020.10.471. Epub ahead of print.

    • Assessment of structural chromosomal instability phenotypes as biomarkers of carboplatin response in Triple Negative Breast Cancer: the TNT trial.
    • Sipos O, Tovey H, Quist J, Haider S, Nowinski S, Gazinska P, Kernaghan S, Toms C, Maguire S, Orr N, Linn SC, Owen J, Gillett C, Pinder SE, Bliss JM, Tutt A, Cheang MCU, Grigoriadis A.
    • Ann Oncol. 2020 Oct 21:S0923-7534(20)42977-1. doi: 10.1016/j.annonc.2020.10.475. Epub ahead of print.

    • Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations.
    • Schmid S, Omlin A, Higano C, Sweeney C, Martinez Chanza N, Mehra N, Kuppen MCP, Beltran H, Condeduca V, Vargas Pivato de Almeida D, Cotait Maluf F, Oh WK, Tsao CK, Sartor O, Ledet E, Di Lorenzo G, Yip SM, Chi KN, Bianchini D, De Giorgi U, Hansen AR, Beer TM, Pernelle L, Morales-Barrera R, Tucci M, Castro E, Karalis K, Bergman AM, Le ML, Zürrer-Härdi U, Pezaro C, Suzuki H, Zivi A, Klingbiel D, Schär S, Gillessen S.
    • JAMA Netw Open. 2020 Oct 1;3(10):e2021692. doi: 10.1001/jamanetworkopen.2020.21692.

    • Pathology of Hereditary Breast and Ovarian Cancer.
    • Hodgson A, Turashvili G.
    • Front Oncol. 2020 Sep 29;10:531790. doi: 10.3389/fonc.2020.531790.

    • LitAlert ~~ GeneLit.com

    • Under-ascertainment of breast cancer susceptibility gene carriers in a cohort of New Zealand female breast cancer patients.
    • Lattimore V, Parsons MT, Spurdle AB, Pearson J, Lehnert K, Sullivan J, Lintott C, Bawden S, Morrin H, Robinson B, Walker L.
    • Breast Cancer Res Treat. 2020 Oct 28. doi: 10.1007/s10549-020-05986-8. Epub ahead of print.

    • Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study.
    • O'Shaughnessy J, Brezden-Masley C, Cazzaniga M, Dalvi T, Walker G, Bennett J, Ohsumi S.
    • Breast Cancer Res. 2020 Oct 27;22(1):114. doi: 10.1186/s13058-020-01349-9.

    • Misinterpretation of Hereditary Breast Cancer Risk and Its Association with Information Sharing Motives among Women at Low Likelihood of Carrying a BRCA1/2 Mutation.
    • Zhao J, McBride CM, Guan Y.
    • Public Health Genomics. 2020 Oct 27:1-5. doi: 10.1159/000511131. Epub ahead of print.

    • Breast Cancer Surveillance Following Ovarian Cancer in BRCA Mutation Carriers.
    • Fong A, Cass I, John C, Gillen J, Moore KM, Gangi A, Walsh C, Li AJ, Rimel BJ, Karlan BY, Amersi F.
    • Am Surg. 2020 Oct 26:3134820964208. doi: 10.1177/0003134820964208. Epub ahead of print.

    • Analysis of 11 candidate genes in 849 adult patients with suspected hereditary cancer predisposition.
    • Cavaillé M, Uhrhammer N, Privat M, Ponelle-Chachuat F, Gay-Bellile M, Lepage M, Molnar I, Viala S, Bidet Y, Bignon YJ.
    • Genes Chromosomes Cancer. 2020 Oct 25. doi: 10.1002/gcc.22911. Epub ahead of print.

    • Predictive factors for carboplatin hypersensitivity reactions in gynecologic cancers: Effect of BRCA status.
    • Rolfe M, Gegeckas C, Turner S, Orr JW Jr.
    • J Oncol Pharm Pract. 2020 Oct 25:1078155220967988. doi: 10.1177/1078155220967988. Epub ahead of print.

    • Alternative genomic diagnoses for individuals with a clinical diagnosis of Dubowitz syndrome.
    • Dyment DA, O'Donnell-Luria A, Agrawal PB, Coban Akdemir Z, Aleck KA, Antaki D, Al Sharhan H, Au PB, Aydin H, Beggs AH, Bilguvar K, Boerwinkle E, Brand H, Brownstein CA, Buyske S, Chodirker B, Choi J, Chudley AE, Clericuzio CL, Cox GF, Curry C, de Boer E, de Vries BBA, Dunn K, Dutmer CM, England EM, Fahrner JA, Geckinli BB, Genetti CA, Gezdirici A, Gibson WT, Gleeson JG, Greenberg CR, Hall A, Hamosh A, Hartley T, Jhangiani SN, Karaca E, Kernohan K, Lauzon JL, Lewis MES, Lowry RB, López-Giráldez F, Matise TC, McEvoy-Venneri J, McInnes B, Mhanni A, Garcia Minaur S, Moilanen J, Nguyen A, Nowaczyk MJM, Posey JE, Õunap K, Pehlivan D, Pajusalu S, Penney LS, Poterba T, Prontera P, Doriqui MJR, Sawyer SL, Sobreira N, Stanley V, Torun D, Wargowski D, Witmer PD, Wong I, Xing J, Zaki MS, Zhang Y; Care4Rare Consortium; Centers for Mendelian Genomics, Boycott KM, Bamshad MJ, Nickerson DA, Blue EE, Innes AM.
    • Am J Med Genet A. 2020 Oct 24. doi: 10.1002/ajmg.a.61926. Epub ahead of print.

    • Impact of Personalized Genetic Breast Cancer Risk Estimation With Polygenic Risk Scores on Preventive Endocrine Therapy Intention and Uptake.
    • Kim JO, Schaid DJ, Vachon CM, Cooke A, Couch FJ, Kim CA, Sinnwell JP, Hasadsri L, Stan DL, Goldenberg BA, Neal L, Grenier D, Degnim AC, Thicke LA, Pruthi S.
    • Cancer Prev Res (Phila). 2020 Oct 23:canprevres.0154.2020. doi: 10.1158/1940-6207.CAPR-20-0154. Epub ahead of print.

    • An in-depth exploration of the post-test informational needs of BRCA1 and BRCA2 pathogenic variant carriers in Asia.
    • Yuen J, Fung SM, Sia CL, Venkatramani M, Shaw T, Courtney E, Li ST, Chiang J, Tan VK, Tan BK, Ngeow J.
    • Hered Cancer Clin Pract. 2020 Oct 23;18:22. doi: 10.1186/s13053-020-00154-x.

    • ICON 9-an international phase III randomized study to evaluate the efficacy of maintenance therapy with olaparib and cediranib or olaparib alone in patients with relapsed platinum-sensitive ovarian cancer following a response to platinum-based chemotherapy.
    • Elyashiv O, Ledermann J, Parmar G, Farrelly L, Counsell N, Feeney A, El-Khouly F, Macdonald I, Neto A, Arthur-Darkwa E, Burnett E, Jayson GC, Mileshkin L, Gourley C, Nicum S.
    • Int J Gynecol Cancer. 2020 Oct 23:ijgc-2020-002073. doi: 10.1136/ijgc-2020-002073. Epub ahead of print.

    • Inflammatory indexes as predictive factors for platinum sensitivity and as prognostic factors in recurrent epithelial ovarian cancer patients: a MITO24 retrospective study.
    • Farolfi A, Scarpi E, Greco F, Bergamini A, Longo L, Pignata S, Casanova C, Cormio G, Bologna A, Orditura M, Zavallone L, Attademo L, Gallà V, Franzese E, Pigozzi E, Loizzi V, Giorda G, Giardina D, Cioffi R, De Giorgi U.
    • Sci Rep. 2020 Oct 23;10(1):18190. doi: 10.1038/s41598-020-75316-x.

    • Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study).
    • Fasching PA, Link T, Hauke J, Seither F, Jackisch C, Klare P, Schmatloch S, Hanusch C, Huober J, Stefek A, Seiler S, Schmitt WD, Uleer C, Doering G, Rhiem K, Schneeweiss A, Engels K, Denkert C, Schmutzler RK, Hahnen E, Untch M, Burchardi N, Blohmer JU, Loibl S; GBG and AGO-B.
    • Ann Oncol. 2020 Oct 21:S0923-7534(20)42963-1. doi: 10.1016/j.annonc.2020.10.471. Epub ahead of print.

    • Assessment of structural chromosomal instability phenotypes as biomarkers of carboplatin response in Triple Negative Breast Cancer: the TNT trial.
    • Sipos O, Tovey H, Quist J, Haider S, Nowinski S, Gazinska P, Kernaghan S, Toms C, Maguire S, Orr N, Linn SC, Owen J, Gillett C, Pinder SE, Bliss JM, Tutt A, Cheang MCU, Grigoriadis A.
    • Ann Oncol. 2020 Oct 21:S0923-7534(20)42977-1. doi: 10.1016/j.annonc.2020.10.475. Epub ahead of print.

    • Activity of Platinum-Based Chemotherapy in Patients With Advanced Prostate Cancer With and Without DNA Repair Gene Aberrations.
    • Schmid S, Omlin A, Higano C, Sweeney C, Martinez Chanza N, Mehra N, Kuppen MCP, Beltran H, Condeduca V, Vargas Pivato de Almeida D, Cotait Maluf F, Oh WK, Tsao CK, Sartor O, Ledet E, Di Lorenzo G, Yip SM, Chi KN, Bianchini D, De Giorgi U, Hansen AR, Beer TM, Pernelle L, Morales-Barrera R, Tucci M, Castro E, Karalis K, Bergman AM, Le ML, Zürrer-Härdi U, Pezaro C, Suzuki H, Zivi A, Klingbiel D, Schär S, Gillessen S.
    • JAMA Netw Open. 2020 Oct 1;3(10):e2021692. doi: 10.1001/jamanetworkopen.2020.21692.

    • LitAlert ~~ GeneLit.com

    • An evaluation of olaparib for the treatment of pancreatic cancer.
    • Vaishampayan UN.
    • Expert Opin Pharmacother. 2020 Oct 23. doi: 10.1080/14656566.2020.1837113. Epub ahead of print.
    • Review

    • Innovations in targeted therapies for triple negative breast cancer.
    • McCann KE, Hurvitz SA.
    • Curr Opin Obstet Gynecol. 2020 Oct 21. doi: 10.1097/GCO.0000000000000671. Epub ahead of print.
    • Review

    • Knowledge and practice regarding prostate cancer germline testing among urologists: Gaps to address for optimal implementation.
    • Loeb S, Byrne N, Walter D, Makarov DV, Wise DR, Becker D, Giri VN.
    • Cancer Treat Res Commun. 2020 Sep 28;25:100212. doi: 10.1016/j.ctarc.2020.100212. Epub ahead of print.

    • Cytologic studies of in vivo fallopian tube specimens in patients undergoing salpingo-oophorectomy.
    • Pramanik S, Yang E, Wu W.
    • Cytojournal. 2020 Aug 10;17:19. doi: 10.25259/CytoJournal_7_2020.

    • LitAlert ~~ GeneLit.com

    • Integration of functional assay data results provides strong evidence for classification of hundreds of BRCA1 variants of uncertain significance.
    • Lyra PCM Jr, Nepomuceno TC, de Souza MLM, Machado GF, Veloso MF, Henriques TB, Dos Santos DZ, Ribeiro IG, Ribeiro RS Jr, Rangel LBA, Richardson M, Iversen ES, Goldgar D, Couch FJ, Carvalho MA, Monteiro ANA.
    • Genet Med. 2020 Oct 22. doi: 10.1038/s41436-020-00991-0. Epub ahead of print.

    • Ideaya Biosciences, Broad Institute Partner on Synthetic Lethality-Based Cancer Drug Discovery.
    • [No author given]
    • GenomeWeb. Technology. Gene Silencing/Gene Editing. 2020 Oct 22.

    • Doing a Better Job at Reaching LatinX People and Families about Hereditary Cancer.
    • Gómez Trillos S, Hurtado de Mendoza A.
    • FORCE. Blog. 2020 Oct 21.

    • LitAlert ~~ GeneLit.com

    • Group Therapy for Patients With Medical Illness.
    • Leszcz M.
    • Am J Psychother. 2020 Oct 22:appipsychotherapy20200005. doi: 10.1176/appi.psychotherapy.20200005. Epub ahead of print.

    • Circulating growth factor concentrations and breast cancer risk: a nested case-control study of IGF-1, IGFBP-3, and breast cancer in a family-based cohort.
    • Monson KR, Goldberg M, Wu HC, Santella RM, Chung WK, Terry MB.
    • Breast Cancer Res. 2020 Oct 22;22(1):109. doi: 10.1186/s13058-020-01352-0.

    • The factors associated with distress a minimum of six months after BRCA1/2 confirmation: A systematic review.
    • Butler E, Collier S, Hevey D.
    • J Psychosoc Oncol. 2020 Oct 22:1-27. doi: 10.1080/07347332.2020.1836109. Epub ahead of print.
    • Review

    • Cell type-specific genotoxicity in estrogen-exposed ovarian and fallopian epithelium.
    • Song L, Tang Z, Peng C, Yang Y, Guo C, Wang D, Guo L, Chen J, Liu C.
    • BMC Cancer. 2020 Oct 21;20(1):1020. doi: 10.1186/s12885-020-07524-7.

    • Genetic testing for breast cancer risk, from BRCA1/2 to a seven gene panel: an ethical analysis.
    • Gustavsson E, Galvis G, Juth N.
    • BMC Med Ethics. 2020 Oct 21;21(1):102. doi: 10.1186/s12910-020-00545-8.

    • Haplotype analysis of the internationally distributed BRCA1 c.3331_3334delCAAG founder mutation reveals a common ancestral origin in Iberia.
    • Tuazon AMA, Lott P, Bohórquez M, Benavides J, Ramirez C, Criollo A, Estrada-Florez A, Mateus G, Velez A, Carmona J, Olaya J, Garcia E, Polanco-Echeverry G, Stultz J, Alvarez C, Tapia T, Ashton-Prolla P; Brazilian Familial Cancer Network, Vega A, Lazaro C, Tornero E, Martinez-Bouzas C, Infante M, De La Hoya M, Diez O, Browning BL; COLUMBUS Consortium, Rannala B, Teixeira MR, Carvallo P, Echeverry M, Carvajal-Carmona LG.
    • Breast Cancer Res. 2020 Oct 21;22(1):108. doi: 10.1186/s13058-020-01341-3.

    • Exome sequencing and characterization of 49,960 individuals in the UK Biobank.
    • Van Hout CV, Tachmazidou I, Backman JD, Hoffman JD, Liu D, Pandey AK, Gonzaga-Jauregui C, Khalid S, Ye B, Banerjee N, Li AH, O'Dushlaine C, Marcketta A, Staples J, Schurmann C, Hawes A, Maxwell E, Barnard L, Lopez A, Penn J, Habegger L, Blumenfeld AL, Bai X, O'Keeffe S, Yadav A, Praveen K, Jones M, Salerno WJ, Chung WK, Surakka I, Willer CJ, Hveem K, Leader JB, Carey DJ, Ledbetter DH; Geisinger-Regeneron DiscovEHR Collaboration, Cardon L, Yancopoulos GD, Economides A, Coppola G, Shuldiner AR, Balasubramanian S, Cantor M; Regeneron Genetics Center, Nelson MR, Whittaker J, Reid JG, Marchini J, Overton JD, Scott RA, Abecasis GR, Yerges-Armstrong L, Baras A.
    • Nature. 2020 Oct 21. doi: 10.1038/s41586-020-2853-0. Epub ahead of print.

    • The DNA damaging revolution.
    • Cetin B, Wabl CA, Gumusay O.
    • Crit Rev Oncol Hematol. 2020 Oct 3;156:103117. doi: 10.1016/j.critrevonc.2020.103117. Epub ahead of print.
    • Review

    • Molecular Biomarkers for Early Detection and Prevention of Ovarian Cancer-A Gateway for Good Prognosis: A Narrative Review.
    • Yadav G, Vashisht M, Yadav V, Shyam R.
    • Int J Prev Med. 2020 Sep 3;11:135. doi: 10.4103/ijpvm.IJPVM_75_19.

    • LitAlert ~~ GeneLit.com

    • Reclassification of BRCA1 and BRCA2 variants found in ovarian epithelial, fallopian tube, and primary peritoneal cancers.
    • Ha HI, Ryu JS, Shim H, Kong SY, Lim MC.
    • J Gynecol Oncol. 2020 Nov;31(6):e83. doi: 10.3802/jgo.2020.31.e83.

    • Frequency and spectrum of mutations across 94 cancer predisposition genes in African American women with invasive breast cancer.
    • Lovejoy LA, Rummel SK, Turner CE, Shriver CD, Ellsworth RE.
    • Fam Cancer. 2020 Oct 21. doi: 10.1007/s10689-020-00213-1. Epub ahead of print.

    • Lessons learned from setting up a prospective, longitudinal, multicenter study with women at high risk for breast cancer.
    • Patuleia SIS, Hagenaars SC, Moelans CB, Ausems MGEM, van Gils CH, Tollenaar RAEM, Van Diest PJ, Mesker WE, van der Wall E.
    • Cancer Epidemiol Biomarkers Prev. 2020 Oct 20:cebp.0770.2020. doi: 10.1158/1055-9965.EPI-20-0770. Epub ahead of print.
    • Review

    • PARP Inhibitors in Cancer Diagnosis and Therapy.
    • Chan CY, Tan KV, Cornelissen B.
    • Clin Cancer Res. 2020 Oct 20:clincanres.2766.2020. doi: 10.1158/1078-0432.CCR-20-2766. Epub ahead of print.
    • Review

    • Germline testing for homologous recombination repair genes - opportunities and challenges.
    • Hirsch S, Gieldon L, Sutter C, Dikow N, Schaaf CP.
    • Genes Chromosomes Cancer. 2020 Oct 20. doi: 10.1002/gcc.22900. Epub ahead of print.
    • Review

    • Tumor site discordance in mismatch repair deficiency in synchronous endometrial and ovarian cancers.
    • Kim SR, Tone A, Kim R, Cesari M, Clarke B, Eiriksson L, Hart T, Aronson M, Holter S, Lytwyn A, Maganti M, Oldfield L, Gallinger S, Bernardini MQ, Oza AM, Djordjevic B, Lerner-Ellis J, Van de Laar E, Vicus D, Pugh TJ, Pollett A, Ferguson SE.
    • Int J Gynecol Cancer. 2020 Oct 20:ijgc-2020-001927. doi: 10.1136/ijgc-2020-001927. Epub ahead of print.

    • ASO Author Reflections: Contralateral Prophylactic Mastectomy in Breast Cancer Patients with CHEK2 Gene Mutations.
    • Nizic-Kos T, Besic N.
    • Ann Surg Oncol. 2020 Oct 18. doi: 10.1245/s10434-020-09196-w. Epub ahead of print.
    • Commentary

    • Repurposing denosumab in breast cancer beyond prevention of skeletal related events: could nonclinical data be translated into clinical practice?
    • Deligiorgi MV, Panayiotidis MI, Trafalis DT.
    • Expert Rev Clin Pharmacol. 2020 Oct 17. doi: 10.1080/17512433.2020.1839416. Epub ahead of print.
    • Review

    • Novel Agents for Metastatic Triple-Negative Breast Cancer: Finding the Positive in the Negative.
    • Vidula N, Ellisen LW, Bardia A.
    • J Natl Compr Canc Netw. 2020 Oct 15:1-9. doi: 10.6004/jnccn.2020.7600. Epub ahead of print.

    • Olaparib treatment in older patients with ovarian cancer: need for 'real-world' data beyond clinical trials.
    • Liposits G, Wulff CN, Otland A, Fokdal LU.
    • Ecancermedicalscience. 2020 Sep 15;14:1104. doi: 10.3332/ecancer.2020.1104.

    • LitAlert ~~ GeneLit.com

    • Reclassification of BRCA1 and BRCA2 variants found in ovarian epithelial, fallopian tube, and primary peritoneal cancers.
    • Ha HI, Ryu JS, Shim H, Kong SY, Lim MC.
    • J Gynecol Oncol. 2020 Nov;31(6):e83. doi: 10.3802/jgo.2020.31.e83.

    • Germline testing for homologous recombination repair genes - opportunities and challenges.
    • Hirsch S, Gieldon L, Sutter C, Dikow N, Schaaf CP.
    • Genes Chromosomes Cancer. 2020 Oct 20. doi: 10.1002/gcc.22900. Epub ahead of print.
    • Review

    • ASO Author Reflections: Contralateral Prophylactic Mastectomy in Breast Cancer Patients with CHEK2 Gene Mutations.
    • Nizic-Kos T, Besic N.
    • Ann Surg Oncol. 2020 Oct 18. doi: 10.1245/s10434-020-09196-w. Epub ahead of print.
    • Commentary

    • Repurposing denosumab in breast cancer beyond prevention of skeletal related events: could nonclinical data be translated into clinical practice?
    • Deligiorgi MV, Panayiotidis MI, Trafalis DT.
    • Expert Rev Clin Pharmacol. 2020 Oct 17. doi: 10.1080/17512433.2020.1839416. Epub ahead of print.
    • Review

    • LitAlert ~~ GeneLit.com

    • Comparison of interval breast cancers with 2D digital mammography versus 3D digital breast tomosynthesis in a large community-based practice.
    • Winter AM, Kazmi S, Hardy AK, Bennett DL.
    • Breast J. 2020 Oct 16. doi: 10.1111/tbj.14047. Epub ahead of print.

    • Genetic and clinical landscape of breast cancers with germline BRCA1/2 variants.
    • Inagaki-Kawata Y, Yoshida K, Kawaguchi-Sakita N, Kawashima M, Nishimura T, Senda N, Shiozawa Y, Takeuchi Y, Inoue Y, Sato-Otsubo A, Fujii Y, Nannya Y, Suzuki E, Takada M, Tanaka H, Shiraishi Y, Chiba K, Kataoka Y, Torii M, Yoshibayashi H, Yamagami K, Okamura R, Moriguchi Y, Kato H, Tsuyuki S, Yamauchi A, Suwa H, Inamoto T, Miyano S, Ogawa S, Toi M.
    • Commun Biol. 2020 Oct 16;3(1):578. doi: 10.1038/s42003-020-01301-9.

    • BRCA1 and BRCA2 genes mutations among high risk breast cancer patients in Jordan.
    • Abu-Helalah M, Azab B, Mubaidin R, Ali D, Jafar H, Alshraideh H, Drou N, Awidi A.
    • Sci Rep. 2020 Oct 16;10(1):17573. doi: 10.1038/s41598-020-74250-2.

    • Clinical characteristics and prognostic implications of BRCA-associated tumors in males: a pan-tumor survey.
    • Sun P, Li Y, Chao X, Li J, Luo R, Li M, He J.
    • BMC Cancer. 2020 Oct 14;20(1):994. doi: 10.1186/s12885-020-07481-1.

    • The mediating effects of public genomic knowledge in precision medicine implementation: A structural equation model approach.
    • Mogaka JJO, Chimbari MJ.
    • PLoS One. 2020 Oct 14;15(10):e0240585. doi: 10.1371/journal.pone.0240585.

    • Genetic counseling in prostate cancer: How to implement it in daily clinical practice?
    • Borque-Fernando A, Espílez R, Miramar D, Corbatón D, Rodríguez A, Castro E, Mateo J, Rello L, Méndez A, Gil Sanz MJ.
    • Actas Urol Esp. 2020 Oct 12:S0210-4806(20)30194-7. English, Spanish. doi: 10.1016/j.acuro.2020.08.009. Epub ahead of print.
    • Review, [Article in Spanish]

    • Newly diagnosed ovarian cancer: Which first-line treatment?
    • Lorusso D, Ceni V, Daniele G, Salutari V, Pietragalla A, Muratore M, Nero C, Ciccarone F, Scambia G.
    • Cancer Treat Rev. 2020 Oct 9;91:102111. doi: 10.1016/j.ctrv.2020.102111. Epub ahead of print.
    • Review

    • Identification of Germline Mutations in Melanoma Patients with Early Onset, Double Primary Tumors, or Family Cancer History by NGS Analysis of 217 Genes.
    • Stolarova L, Jelinkova S, Storchova R, Machackova E, Zemankova P, Vocka M, Kodet O, Kral J, Cerna M, Volkova Z, Janatova M, Soukupova J, Stranecky V, Dundr P, Foretova L, Macurek L, Kleiblova P, Kleibl Z.
    • Biomedicines. 2020 Oct 9;8(10):E404. doi: 10.3390/biomedicines8100404.

    • Significance of E-cadherin Gene Mutations in Patients With Hereditary Diffuse Gastric Cancer Syndrome: A Systematic Review.
    • Goud HK, Mehkari Z, Mohammed L, Javed M, Althwanay A, Ahsan F, Oliveri F, Rutkofsky IH.
    • Cureus. 2020 Sep 12;12(9):e10406. doi: 10.7759/cureus.10406.

    • LitAlert ~~ GeneLit.com

    • Rare Germline Genetic Variants and the Risks of Epithelial Ovarian Cancer.
    • Pavanello M, Chan IHY, Ariff A, Pharoah PDP, Gayther SA, Ramus SJ.
    • Cancers (Basel). 2020 Oct 19;12(10):E3046. doi: 10.3390/cancers12103046.

    • Testing a Best Practices Risk Result Format to Communicate Genetic Risks.
    • Davis K, Roter DL, Schmidlen T, Scheinfeldt LB, Klein WMP.
    • Patient Educ Couns. 2020 Oct 19:S0738-3991(20)305589. doi: 10.1016/j.pec.2020.10.021. Epub ahead of print.

    • How Patients Deal with an Ambiguous Medical Test: Decision-Making after Genetic Testing.
    • Scherra CL, Ramesh S, Getachew-Smith H, Kalke K, Ramsey K, Fischhoff B, Vadaparampil ST.
    • Patient Educ Couns. 2020 Oct 18:S0738-3991(20)305577. doi: 10.1016/j.pec.2020.10.020. Epub ahead of print.

    • LitAlert ~~ GeneLit.com

    • Comparison of Poly (ADP-ribose) Polymerase Inhibitors (PARPis) as Maintenance Therapy for Platinum-Sensitive Ovarian Cancer: Systematic Review and Network Meta-Analysis.
    • Stemmer A, Shafran I, Stemmer SM, Tsoref D.
    • Cancers (Basel). 2020 Oct 18;12(10):E3026. doi: 10.3390/cancers12103026.

    • Isoflavone intake on the risk of overall breast cancer and molecular subtypes in women at high risk for hereditary breast cancer.
    • Sim EJ, Ko KP, Ahn C, Park SM, Surh YJ, An S, Kim SW, Lee MH, Lee JW, Lee JE, Kim KS, Yom CK, Kim HA, Park SK.
    • Breast Cancer Res Treat. 2020 Oct 17. doi: 10.1007/s10549-020-05875-0. Epub ahead of print.

    • Development and Implementation of an Algorithm to Guide MRI Screening in Patients with a Personal History of Treated Breast Cancer.
    • Strigel RM, Bravo E, Tevaarwerk AJ, Anderson BM, Stella AL, Neuman HB.
    • Clin Breast Cancer. 2020 Oct 17:S1526-8209(20)30021-5. doi: 10.1016/j.clbc.2020.01.005. Epub ahead of print.